CEL-SCI
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 44
- Market Cap
- $68.8M
- Introduction
CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts
- Conditions
- Perianal Warts
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- CEL-SCI Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT03038828
- Locations
- 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
- Conditions
- Squamous Cell Carcinoma of the Oral CavitySquamous Cell Carcinoma of the Soft Palate
- Interventions
- Biological: LIDietary Supplement: ZincProcedure: SurgeryRadiation: Radiotherapy
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- CEL-SCI Corporation
- Target Recruit Count
- 928
- Registration Number
- NCT01265849
- Locations
- 🇺🇸
Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois, United States
🇺🇸Henry Ford Health System Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
News
CEL-SCI Raises $5.7M to Fund Pivotal Multikine Trial for Head and Neck Cancer
CEL-SCI Corporation completed a $5.7 million stock offering to fund its confirmatory Phase 3 trial for Multikine, a neoadjuvant immunotherapy targeting head and neck cancer patients with low PD-L1 expression.
CEL-SCI Secures $5 Million in Public Offering to Advance Multikine Immunotherapy for Head and Neck Cancer
CEL-SCI Corporation has raised $5 million through a public offering of 2 million shares at $2.50 per share to fund the continued development of its cancer immunotherapy Multikine.
CEL-SCI Advances Multikine for Head and Neck Cancer with FDA-Cleared 212-Patient Registration Study
CEL-SCI received FDA clearance for a 212-patient confirmatory registration study of Multikine in squamous cell head and neck cancer patients with specific biomarker criteria.
CEL-SCI's Multikine Demonstrates Promising Tumor Regression, Advances to Confirmatory Phase 3 Trial for Head and Neck Cancer
CEL-SCI's Multikine showed significant pre-surgical tumor regression in head and neck cancer patients within three weeks, a finding confirmed by pathology.
CEL-SCI Secures $5 Million in Public Offering to Advance Multikine Cancer Immunotherapy
CEL-SCI Corporation has priced a $5 million public offering of 16.13 million shares at $0.31 per share to fund continued development of Multikine, a first-line cancer immunotherapy.
CEL-SCI's Multikine Receives FDA Approval for Confirmatory Head and Neck Cancer Study
CEL-SCI's Multikine has received FDA approval for a confirmatory registration study involving 212 patients with head and neck cancer.
CEL-SCI Partners with Ergomed for Multikine Confirmatory FDA Registration Study in Head and Neck Cancer
CEL-SCI has partnered with Ergomed for a confirmatory FDA registration study of Multikine in head and neck cancer, building on prior successful collaborations.